Research on families with early-onset Alzheimer’s disease has revealed a genetic abnormality that can delay early symptoms by five years. This finding paves the way for a new approach to combating the disease by potentially leveraging the protective effects of this gene mutation. A very rare genetic mutation offers some hope in the fight against Alzheimer’s.
Scientists first noticed this genetic protection in a Colombian family afflicted with a hereditary form of Alzheimer’s disease. They identified a woman, Aliria Piedrahita de Villegas, who should have developed symptoms in her 40s but remained symptom-free well into her 70s. She carried an unusual genetic combination, including two copies of the APOE3 gene with a mutation known as Christchurch, which seemed to provide her with protection against Alzheimer’s.
Further research identified 27 individuals with one copy of the Christchurch variant, showing that having one copy delayed the onset of cognitive impairment by an average of five years compared to their relatives. The study, published in the New England Journal of Medicine and involving researchers from various institutions, provided hope that correcting this gene could potentially slow the progression of Alzheimer’s.
Notably, Alzheimer’s typically affects older individuals, with risk increasing with age. The APOE gene has long been associated with the disease, with certain variants like APOE4 increasing risk. However, the Christchurch variant appears to play a protective role, potentially preventing the accumulation of the proteins amyloid and tau that are linked to Alzheimer’s.
The study included brain scans and autopsy results from individuals with the Christchurch gene, shedding light on its potential impact on Alzheimer’s progression. While there is still much to learn about this rare mutation and its effects, there is optimism that it could offer insights into treating Alzheimer’s and potentially delaying its onset.
Source: www.nbcnews.com
